RBC gives Angiotech outperform rating

Angiotech Pharmaceuticals Inc. was rated at outperform by RBC Capital Markets analyst Douglas Miehm. The company highlighted the AMI acquisition at its annual analyst day. The company indicated it plans to sign another major licensing agreement with a large strategic partner by year-end. Angiotech also signed a definitive agreement to acquire privately held Quill Medical for $40 million in cash plus additional payments based on product revenues. Shares of the Vancouver, B.C., pharmaceutical company were up 19 cents, or 1.35%, at $14.23 on volume of 284,685 shares versus the three-month running average of 275,917 shares. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.